Stockreport

Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson’s Disease at the American Academy of Neurology Annual Meeting

Voyager Therapeutics, Inc.  (VYGR) 
Last voyager therapeutics, inc. earnings: 3/3 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.voyagertherapeutics.com
PDF Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson’s Disease Treatment with VY-AADC Improved Good [Read more]